NewsMV
regulators have granted accelerated approval to sevabertinib, Bayer's (BAYRY) targeted therapy for HER2-mutated non-small cell lung cancer, clearing it as a first-line treatment option in that genetically defined patient population.
The clearance places the drug at the front of the treatment sequence in a molecularly selected lung cancer subset, under a conditional commercial license.
The setup The accelerated approval pathway is conditional by design.
Regulators use it when a drug demonstrates early clinical benefit in an area where patients have limited options, allowing commercial use to begin before the full confirmatory picture is in.
Keep reading